Atrial Fibrillation - Pipeline Insight, 2021

This “Atrial fibrillation - Pipeline Insight, 2021,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Atrial fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Atrial fibrillation Understanding

Atrial fibrillation: Overview

Atrial fibrillation is an irregular and often rapid heart rate that occurs when the two upper chambers of the heart experience chaotic electrical signals. During this condition, the heart's two upper chambers (the atria) beat chaotically and irregularly out of coordination with the two lower chambers (the ventricles) of the heart. Atrial fibrillation symptoms often include heart palpitations, shortness of breath and weakness. A major concern related to atrial fibrillation is the development of blood clots within the upper chambers of the heart. The blood clots formed in the heart may circulate to other organs and result in blocked blood flow (ischemia). The goals of treatment for atrial fibrillation include regaining a normal heart rhythm (sinus rhythm), controlling the heart rate, preventing blood clots and reducing the risk of stroke. Treatment options include lifestyle changes, medications, catheter-based procedures and surgery.

"Atrial fibrillation - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atrial fibrillation pipeline landscape is provided which includes the disease overview and Atrial fibrillation treatment guidelines. The assessment part of the report embraces, in depth Atrial fibrillation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atrial fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve Atrial fibrillation.

Atrial fibrillation Emerging Drugs Chapters

This segment of the Atrial fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atrial fibrillation Emerging Drugs

Etripamil: Milestone Pharmaceuticals

Etripamil is designed to be a rapid-response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered via a nasal spray, which may shift the current treatment paradigm for many patients with PSVT from the emergency department to the at-home setting. The drug is in Phase III clinical studies for the treatment of paroxysmal supraventricular tachycardia and in Phase II clinical studies to treat atrial fibrillation.

GENCARO: ARCA biopharma

Gencaro (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator. The drug is in Phase II/III clinical studies for the treatment and prevention of recurrent atrial fibrillation, or AF, in patients with heart failure with mid-range ejection fraction, or HFmrEF.

Atrial fibrillation: Therapeutic Assessment

This segment of the report provides insights about the different Atrial fibrillation drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Atrial fibrillation

There are approx. 18+ key companies which are developing the therapies for Atrial fibrillation. The companies which have their Atrial fibrillation drug candidates in the most advanced stage, i.e. Phase III include, ARCA biopharma.

Phases

This report covers around 18+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Atrial fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atrial fibrillation: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Atrial fibrillation therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrial fibrillation drugs.

Atrial fibrillation Report Insights

• Atrial fibrillation Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Atrial fibrillation Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Atrial fibrillation drugs?
• How many Atrial fibrillation drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atrial fibrillation?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atrial fibrillation therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atrial fibrillation and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ARCA biopharma
• Milestone Pharmaceuticals
• Armaron Biosciences
• Ono Pharmaceutical
• Gilead Sciences
• Merz Pharma
• Hanmi Pharmaceutical
• InCarda Therapeutics
• HUYA Bioscience International
• Hyloris Pharmaceuticals
• Vivasc Therapeutics
• Espero BioPharma

Key Products

• Gencaro
• Etripamil
• OMT 28
• NP 202
• Landiolol hydrochloride
• Ranolazine extended release
• Botulinum toxin A
• HIP-2001
• Flecainide inhalation
• Sulcardine
• HY-CVS-033
• CTP-amio
• ESP-001

This product will be delivered within 2 business days.